Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Launched by APPLIED BIOLOGY, INC. · Jul 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two treatments, DA-002 and DA-005, to see how safe and effective they are for people experiencing hair loss due to androgenetic alopecia, which includes both male and female pattern baldness. The trial is currently not recruiting participants, but when it starts, it will be open to adults aged 18 and older who have been diagnosed with this type of hair loss and are generally healthy. Participants will need to be willing to follow the treatment instructions and attend regular visits to ensure the study runs smoothly.

To join the trial, participants should not have any recent serious medical issues, such as a stroke or heart attack, and cannot be pregnant or breastfeeding. They should also avoid using other hair loss treatments or medications in the area being studied for at least 30 days before starting the trial. If you are interested in participating, be prepared to discuss your medical history and ensure you can commit to the study's requirements. This trial aims to find new options for treating hair loss, which could help many people feel more confident about their appearance.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • Diagnosed with androgenetic alopecia
• • Willing and able to apply the treatment as directed, comply with study
• • Otherwise healthy
• • Able to give informed consent
• Exclusion Criteria:
• • A medical history that may interfere with study objectives
• • Women who are pregnant, lactating, or planning to become pregnant during the study period
• • Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
• • Subjects who have known allergies to any excipient in DA-002 or DA-005
• • Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation
• • Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation
• • Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation
• • Subject is unable to provide consent or make the allotted clinical visits